Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process

Abstract Imetelstat is a specific and competitive inhibitor of telomerase enzymatic activity. We demonstrated that imetelstat could interfere with the DNA repair process and enhance the effect of DNA damaging agents using hematological tumor cell lines. Short-term administration of imetelstat enhanced growth suppression by anticancer agents and radiation. It also upregulated γH2AX expression induced by irradiation. Immunofluorescence staining showed that both human telomerase reverse transcriptase (hTERT) and γH2AX were upregulated and co-localized in the nucleus of peripheral blood mononuclear cells after irradiation, suggesting that hTERT was involved in the DNA-DSB repair process. Imetelstat enhanced growth inhibitory effect of cytotoxic agents in short-term culture without shortening of telomeres, indicating that this effect was attributed by telomere length independent mechanism. Our results suggest that the combination of short-term treatment with imetelstat and cytotoxic agent is a promising strategy to treat a wide variety of hematopoietic malignancies.

[1]  Y. Kakinoki,et al.  Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study , 2018, Clinical lymphoma, myeloma & leukemia.

[2]  Zachary D Schrank,et al.  Oligonucleotides Targeting Telomeres and Telomerase in Cancer , 2018, Molecules.

[3]  Sunny Y. Yang,et al.  Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics , 2018, Molecular Cancer Research.

[4]  P. Chartrand,et al.  Cell cycle–dependent spatial segregation of telomerase from sites of DNA damage , 2017, The Journal of cell biology.

[5]  A. Allegra,et al.  Telomerase and telomere biology in hematological diseases: A new therapeutic target. , 2017, Leukemia research.

[6]  Q. Wei,et al.  Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma , 2017, Oncotarget.

[7]  J. Merlio,et al.  Telomerase Activation in Hematological Malignancies , 2016, Genes.

[8]  J. Shay,et al.  Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies , 2016, Genome Medicine.

[9]  J. Shay,et al.  Role of Telomeres and Telomerase in Aging and Cancer. , 2016, Cancer discovery.

[10]  R. Laborde,et al.  A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.

[11]  M. McDevitt,et al.  Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. , 2015, The New England journal of medicine.

[12]  P. L. Bergsagel,et al.  Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome , 2014, Proceedings of the National Academy of Sciences.

[13]  V. Tergaonkar,et al.  Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. , 2014, Cancer research.

[14]  Ying Yan,et al.  Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells , 2014, PloS one.

[15]  R. Pieters,et al.  Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia , 2012, Leukemia.

[16]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[17]  M. Bergqvist,et al.  Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. , 2012, Biochimica et biophysica acta.

[18]  D. Baird,et al.  Telomere dysfunction and its role in haematological cancer , 2012, British journal of haematology.

[19]  T. Brümmendorf,et al.  Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT , 2010, Leukemia.

[20]  Y. Nordenberg,et al.  Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms , 2010, PloS one.

[21]  Changyu Shen,et al.  The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel , 2009, Molecular Cancer Therapeutics.

[22]  D. Gilliland,et al.  Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms , 2009, Leukemia.

[23]  S. Kyo,et al.  Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers , 2008, Cancer science.

[24]  J. Shay,et al.  Actions of human telomerase beyond telomeres , 2008, Cell Research.

[25]  A. Protopopov,et al.  Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo , 2008, Leukemia.

[26]  C. Mondello,et al.  Contribution of telomerase RNA retrotranscription to DNA double-strand break repair during mammalian genome evolution , 2007, Genome Biology.

[27]  R. Kolodner,et al.  Chromosome healing by de novo telomere addition in Saccharomyces cerevisiae , 2006, Molecular microbiology.

[28]  M. Manns,et al.  Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma , 2005, Hepatology.

[29]  C. Harley,et al.  Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition , 2005, Oncogene.

[30]  W. Hahn,et al.  The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Holyoake,et al.  Dysregulated expression of the major telomerase components in leukaemic stem cells , 2005, Leukemia.

[32]  M. Rocchi,et al.  Insertion of telomeric repeats at intrachromosomal break sites during primate evolution. , 2004, Genome research.

[33]  T. Pandita,et al.  Telomere stability correlates with longevity of human beings exposed to ionizing radiations. , 2003, Oncology reports.

[34]  J. Shay,et al.  Human Telomerase and Its Regulation , 2002, Microbiology and Molecular Biology Reviews.

[35]  J. Riou,et al.  Telomerase: a therapeutic target for the third millennium? , 2000, Critical reviews in oncology/hematology.

[36]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[37]  I. Weissman,et al.  Telomerase activity in hematopoietic cells is associated with self-renewal potential. , 1996, Immunity.

[38]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.